D.C. appeals court sides with HHS in 340B drug discount program rebate challenge
fiercehealthcare - The ruling upheld a previous decision that pharma companies cannot impose rebates without HHS Secretary approval.
AI Summary: The D.C. appeals court sided with HHS in a legal challenge over 340B drug discount rebates, affirming federal authority over the program’s rebate models. The ruling preserves HHS policy changes that influence pricing and hospital participation, potentially reshaping pharmacy discounts and provider finances nationwide.
- Appeals court and federal rulings cement HHS 340B authority (3)
- CMS reimbursement shakeup: winners, losers and litigation fallout (3)
- HRSA’s revised 340B rebate pilot and oversight push (3)
Appeals court and federal rulings cement HHS 340B authority
CMS reimbursement shakeup: winners, losers and litigation fallout
HRSA’s revised 340B rebate pilot and oversight push
Related Stories
Congress moves to curb HHS' 340B rebate pilot with bill / 4 wks
Hospitals protest as Eli Lilly withholds 340B drug discounts nationwide / 2 months
Tampa General sues Eli Lilly over pulled 340B discounts / 1 month
Eli Lilly demands 340B claims data or cuts hospitals off / 3 months
340B discounts face reform as profits outpace patient benefit / 4 months
AbbVie sues HHS over 340B patient definition and guidance / 4 months
CMS ends Medicare Part D premium subsidy for drug plans / 5 wks
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Oncology, Animal Health, Medicare Advantage (not listed), Reproductive Health and look for the RSS link.
StackHealth Time Machine